Clinical Profile of Patients with Cerebral Palsy
International Journal of Current Pharmaceutical Review and Research · 13.05.2026 · 18 (04)
DOI: 10.25258/ijcpr.18.4.241 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 13.05.2026. Verfasst von Shahbazkhan M. Ghasura und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Cerebral palsy (CP) is one of the most common causes of chronic childhood disability and results from non-progressive injury to the developing brain. It is frequently associated with multiple neurological, developmental, nutritional, and musculoskeletal comorbidities that significantly affect functional outcome and quality of life. Identification of etiological factors and associated disabilities is essential for early intervention and rehabilitation planning.
Aim
To comprehensively investigate the clinical profile, etiological factors, and associated disabilities in children with cerebral palsy. Materials and Methods: This cross-sectional observational study was conducted from January 2023 to December 2023 among children with cerebral palsy attending physiotherapy clinics, rehabilitation centers, and the Departments of Pediatrics and Neurology at Sardar Vallabhbhai Patel Institute of Medical Sciences and Research and SCL Hospital, Ahmedabad. A total of 90 children aged 1–12 years diagnosed with cerebral palsy were included using consecutive sampling. Detailed demographic, antenatal, intranatal, postnatal, developmental, and clinical information was collected using a predesigned proforma after obtaining informed consent from caregivers. Clinical classification of cerebral palsy, Gross Motor Function Classification System (GMFCS) grading, associated disabilities, comorbidities, nutritional assessment, and treatment details were evaluated. Data were analyzed using descriptive statistical methods.
Results
The majority of children belonged to the age group of 2–5 years, with a mean age at diagnosis of 4.21 ± 2.58 years. Male predominance was observed (64.4%). Spastic cerebral palsy was the most common subtype (76.7%), with quadriplegia (30%) and diplegia (28.9%) being the predominant forms. Delayed cry at birth (58.9%), low birth weight (40%), prematurity (32.2%), and severe birth asphyxia (40%) were the major etiological factors. NICU admission was required in 83.3% of children. Most children belonged to GMFCS Levels 3 and 4, indicating moderate to severe functional disability. Epilepsy was the most common associated disability (50%), followed by contractures (30%), feeding difficulties (25.6%), and severe acute malnutrition (25.6%). Physiotherapy was being received by 86.7% of children, while 61.1% were on antiepileptic medications.
Conclusion
Spastic cerebral palsy was the predominant subtype among affected children, and perinatal factors such as birth asphyxia, prematurity, and low birth weight were major etiological contributors. A high prevalence of associated disabilities and nutritional problems was observed. Early identification, multidisciplinary rehabilitation, nutritional support, and improved antenatal and neonatal healthcare services are essential to reduce disease burden and improve functional outcomes in children with cerebral palsy.
Zitieren
APA
Ghasura, S. M., Bhatiya, K. K. C., & Chamar, K. K. (2026). Clinical Profile of Patients with Cerebral Palsy. International Journal of Current Pharmaceutical Review and Research, 18(04). https://doi.org/10.25258/ijcpr.18.4.241
Vancouver
Ghasura SM, Bhatiya KKC, Chamar KK. Clinical Profile of Patients with Cerebral Palsy. International Journal of Current Pharmaceutical Review and Research. 2026;18(04). doi:10.25258/ijcpr.18.4.241
BibTeX
@article{Ghasura2026,
author = {Ghasura, Shahbazkhan M. and Bhatiya, Kamlesh Kumar C. and Chamar, Kishan Kanubhai},
title = {Clinical Profile of Patients with Cerebral Palsy},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {04},
doi = {10.25258/ijcpr.18.4.241}
}
EUVIMED